Pall BioSupport introduces Accuwik lateral flow medium:
This article was originally published in Clinica
Pall's BioSupport Division (US) has introduced Accuwik lateral flow transfer medium as a replacement for nitrocellulose in one-step lateral flow diagnostic tests. The microporous, microfibre membrane contains no surfactants, and is intrinsically hydrophilic, requiring no pre-wetting, the company says. Wicking rate is controllable at migration speeds up to five times faster than nitrocellulose, and the medium exhibits very low level protein adsorption. Three grades, each providing two flow rates depending on orientation, are available.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.